Yes, you are quite right to point out the small phase 1 sample size but what Cashy said above in reply is important #: 72828706. But also, that from quite early on ithe suppression of inflammations associated with MND was noted, along with the positive results for critical biomarkers. Finally, I trust in the long medical and research experience of the trial leaders professors Mathers and Rowe. What they have said and requested is very encouraging.
Yes, you are quite right to point out the small phase 1 sample...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.015(7.32%) |
Mkt cap ! $87.1M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.0¢ | 21.0¢ | $134.7K | 629.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 24563 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 64222 | 3 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
21.5¢ |
Change
0.015 ( 2.38 %) |
||||
| Open | High | Low | Volume | ||
| 21.0¢ | 22.0¢ | 21.0¢ | 340156 | ||
| Last updated 15.57pm 07/06/2024 ? | |||||
| PAA (ASX) Chart |